Söndag 13 Juli | 08:27:14 Europe / Stockholm

Bifogade filer

Kalender

Est. tid*
2026-02-17 08:30 Bokslutskommuniké 2025
2025-11-19 08:30 Kvartalsrapport 2025-Q3
2025-08-29 08:30 Kvartalsrapport 2025-Q2
2025-05-16 - X-dag ordinarie utdelning IVACC 0.00 SEK
2025-05-14 - Årsstämma
2025-05-14 - Kvartalsrapport 2025-Q1
2025-02-13 - Bokslutskommuniké 2024
2025-01-31 - Extra Bolagsstämma 2024
2024-11-14 - Kvartalsrapport 2024-Q3
2024-08-30 - Kvartalsrapport 2024-Q2
2024-06-13 - X-dag ordinarie utdelning IVACC 0.00 SEK
2024-05-15 - Årsstämma
2024-05-15 - Kvartalsrapport 2024-Q1
2024-02-16 - Bokslutskommuniké 2023
2023-11-23 - Extra Bolagsstämma 2023
2023-11-16 - Kvartalsrapport 2023-Q3
2023-08-31 - Kvartalsrapport 2023-Q2
2023-06-08 - X-dag ordinarie utdelning IVACC 0.00 SEK
2023-06-07 - Årsstämma
2023-05-03 - Kvartalsrapport 2023-Q1
2023-02-17 - Bokslutskommuniké 2022
2022-11-10 - Kvartalsrapport 2022-Q3
2022-08-31 - Kvartalsrapport 2022-Q2
2022-06-15 - X-dag ordinarie utdelning IVACC 0.00 SEK
2022-06-14 - Årsstämma
2022-05-20 - Kvartalsrapport 2022-Q1
2022-02-18 - Bokslutskommuniké 2021
2021-11-11 - Kvartalsrapport 2021-Q3
2021-08-31 - Kvartalsrapport 2021-Q2
2021-06-10 - X-dag ordinarie utdelning IVACC 0.00 SEK
2021-06-09 - Årsstämma
2021-05-21 - Kvartalsrapport 2021-Q1
2021-02-18 - Bokslutskommuniké 2020
2020-11-12 - Kvartalsrapport 2020-Q3
2020-08-27 - Kvartalsrapport 2020-Q2
2020-06-12 - X-dag ordinarie utdelning IVACC 0.00 SEK
2020-06-11 - Årsstämma
2020-05-14 - Kvartalsrapport 2020-Q1
2020-02-21 - Bokslutskommuniké 2019
2019-11-28 - Kvartalsrapport 2019-Q3
2019-08-30 - Kvartalsrapport 2019-Q2
2019-06-12 - X-dag ordinarie utdelning IVACC 0.00 SEK
2019-06-11 - Årsstämma
2019-05-29 - Kvartalsrapport 2019-Q1
2019-02-22 - Bokslutskommuniké 2018
2018-11-29 - Kvartalsrapport 2018-Q3
2018-08-30 - Kvartalsrapport 2018-Q2
2018-06-14 - Årsstämma
2018-05-30 - X-dag ordinarie utdelning IVACC 0.00 SEK
2018-05-25 - Kvartalsrapport 2018-Q1
2018-03-09 - Extra Bolagsstämma 2018
2018-02-15 - Bokslutskommuniké 2017
2017-11-27 - Kvartalsrapport 2017-Q3
2017-08-28 - Kvartalsrapport 2017-Q2
2017-06-08 - Årsstämma
2017-05-24 - Kvartalsrapport 2017-Q1

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
Intervacc är en koncern inom djurhälsa som utvecklar vaccin för djur. Bolaget utvecklar och säljer vaccin mot djursjukdomar baserat på den egenutvecklade teknikplattformen med fusionerade rekombinanta proteiner. Försäljningen sker idag via egen organisation inom Norden och via partnern Dechra Pharmaceuticals i övriga Europa. Bolagets huvudkontor ligger i Hägersten.
2020-03-25 23:55:27

Stockholm 25 March 2020 - Intervacc AB (publ) will continue the development of its new vaccine against Staphylococcus aureus infections that cause mastitis in dairy cows. The project will be co-financed by Intervacc and Vinnova within the framework of innovation projects at small and medium-sized companies - Autumn 2019. Financing covers a part of the preclinical phase of the development program with a budget of SEK 3.9 million.

Vinnova has motivated its decision, which was made in face of strong competition from other applications, with the following comments:
  • The project results are considered to provide a good basis for a positive contribution to one or more of the goals for sustainable development in the UN Agenda 2030 platform. Furthermore, the company's analysis of any risks linked to the sustainability goals and actions is considered to be well thought-out.
  • The project plan is detailed and describes a clearly focused and feasible project. The project budget is judged to be credible.
  • The company's resources in the form of previous experience, as well as skills, networks and equipment provide a good basis for achieving the project goals.

"This is a very good validation of our operations and our vaccine technology, as well as of our vaccine candidates against mastitis in dairy cows. Vinnova has selected our innovation project in the face of strong competition from other Swedish development projects, all with the potential to achieve international success. We can now strengthen our activities in this vaccine development in our exciting project portfolio of modern vaccines" said Jan-Ingmar Flock, chief scientific officer at Intervacc.

Mastitis in dairy cows is a major problem in the dairy industry worldwide. In the EU alone, more than 2.6 million cases of mastitis, which can be linked to Staphylococcus aureus, occur per year. The global milk industry costs associated with mastitis are almost SEK 270 billion. The dairy industry is affected, among other things, by reduced milk yield, financial losses due to low milk quality, discarded milk and premature slaughter of productive dairy cattle. The need for a new effective vaccine to complement other preventive measures is very high.

The need for new effective vaccines is increasing

Recent events have created a focus on the need for new and safe vaccines. The fight against antibiotic-resistant bacteria and diseases that are spreading globally is a priority. This war is being waged in both human and animal medicine, in line with the principles of "one health". Many infections that affect humans originate in animals and spread to humans. This also applies to bacteria that have developed antibiotic resistance. In this context, the development of new effective vaccines for prophylactic treatment plays an important role in reducing the worldwide use of antibiotics.

For more information please contact:                    

Andreas Andersson, CEO

Phone: +46 (0)8 120 10 601, Cell: +46 (0)73 335 99 70

E-mail: andreas.andersson@intervacc.com

 

This information is information that Intervacc AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above on March 25, 2020.

 

About Intervacc

Intervacc AB (publ) is a company within the Biotechnology sector. The Company's main area is to develop modern sub-unit vaccines against economically important bacterial infections, within animal health. The company's vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Research where the foundation was laid for the company's research and development work. The Intervacc share has been listed on the NASDAQ First North Growth Market since April 2017 with Eminova Fondkommission AB, adviser@eminova.se,+46 (0)8-684 211 10 as Certified Adviser.

 

About Vinnova

Vinnova is Sweden's innovation authority. Vinnova's mission is to promote sustainable growth in Sweden through funding of needs-motivated research and development of effective innovation systems. Vinnova is a government agency under the Ministry of Trade and Industry and national contact authority for the EU framework program for research and development.

 

Contact information for Certified Adviser

Eminova Fondkommission AB

E-mail: adviser@eminova.se,Phone: +46 (0)8 - 684 211 10